Hengrui Pharma Q3 2026 net profit attributable to shareholders jumps 89% to RMB 2.46 billion

• Hengrui Pharma's third-quarter 2026 net profit attributable to shareholders jumped 89% to RMB 2.46 billion; revenue rose 21% to RMB 8.95 billion.
• First-nine-month 2026 net profit attributable to shareholders climbed 20% to RMB 6.92 billion; revenue increased 5% to RMB 24.41 billion.
• Innovative-drug out-licensing revenue grew 31% to RMB 2.78 billion in the first nine months of 2026.
• The HRS-1596 licensing deal with Novo Nordisk is worth up to US$ 2.6 billion, including US$ 300 million upfront.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.